Search - tctmd.com

Displaying 21 - 40 of 67

Sort: Relevancy | Date

Presentation AHA 2023

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

November 11, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

Presentation AHA 2022

Reduction of Lipoprotein(a) With Small Interfering RNA: Results of the OCEAN(a)-DOSE (TIMI 67) Trial

Presenter: Michelle L. O’Donoghue

November 07, 2022

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Conference News AHA 2021

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Michael O'Riordan

November 22, 2021

News Conference News AHA 2021

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

Shelley Wood

November 15, 2021

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Todd Neale

November 15, 2021

News Conference News AHA 2021

Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients

Michael O'Riordan

November 13, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Conference News AHA 2020

No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk

Michael O'Riordan

November 19, 2020

News Conference News AHA 2020

Obesity Worsens Outcomes in COVID-19, Especially for Younger Adults

Shelley Wood

November 18, 2020

News Conference News AHA 2020

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

Michael O'Riordan

November 15, 2020

News Conference News AHA 2020

OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients

Todd Neale

November 15, 2020

News Conference News AHA 2020

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

Todd Neale

November 15, 2020

News Conference News AHA 2020

One Pill to Treat Them All: Polycap Strategy Sees Success in TIPS-3

Michael O'Riordan

November 13, 2020

News Conference News AHA 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Michael O'Riordan

November 12, 2020

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

News Conference News AHA 2019

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

Caitlin E. Cox

November 19, 2019

Advertisement

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Reduction of Lipoprotein(a) With Small Interfering RNA: Results of the OCEAN(a)-DOSE (TIMI 67) Trial

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

ApoB Gains Ground as Best Lipid Predictor of MI Risk

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk

Obesity Worsens Outcomes in COVID-19, Especially for Younger Adults

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

One Pill to Treat Them All: Polycap Strategy Sees Success in TIPS-3

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content